News | December 22, 2025
CORONA Remedies commissions additional capacity
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Medico Remedies receives order worth US$ 1,781,000
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Subscribe To Our Newsletter & Stay Updated
